Renewed Distribution And Digital Adoption Will Improve Healthcare Supply Chains

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Feb 25

Updated

18 Oct 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-23.9%

7D

-2.2%

Loading

1Y

-23.9%

7D

-2.2%

You can edit this narrative until Oct 19 8:05 PM. Then, changes will post as Updates.

Author's Valuation

NZ$32.6414.6% undervalued

AnalystConsensusTarget Fair Value

Shared on 18 Oct 25

Fair value Decreased 12%

Analysts have revised their price target for EBOS Group downward from $36.96 to $32.64. This adjustment is due to lowered revenue growth expectations, while profit margins and discount rates remain stable.

Shared on 17 Sep 25

Fair value Decreased 2.62%

EBOS Group’s consensus price target has been revised downward as a result of an increased future P/E ratio without a meaningful improvement in revenue growth expectations, reducing the fair value estimate from NZ$37.96 to NZ$36.96. What's in the News EBOS Group announced a supplementary dividend distribution of NZD 0.02713235 for the six months ended June 30, 2026; record date is 5 September, ex-date is 4 September, and payment date is 24 September.

Shared on 28 Aug 25

Fair value Decreased 3.96%

A slight rise in EBOS Group’s future P/E ratio, with virtually unchanged revenue growth forecasts, suggests increased valuation multiples underpin a marginal decrease in the consensus analyst price target from NZ$39.53 to NZ$38.95. Valuation Changes Summary of Valuation Changes for EBOS Group The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from NZ$39.53 to NZ$38.95.

Shared on 01 May 25

Fair value Decreased 3.41%

Shared on 23 Apr 25

Fair value Increased 1.54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 0.72%

AnalystConsensusTarget has increased revenue growth from 3.6% to 4.1%.

Shared on 09 Apr 25

Fair value Increased 0.65%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 1.90%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.52%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 1.94%

AnalystConsensusTarget has decreased revenue growth from 4.1% to 3.3%.

Shared on 12 Mar 25

Fair value Decreased 0.73%

AnalystConsensusTarget Fair Value

NZ$32.64

14.6% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

5.49%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.10%

Calculation

AU$283.43m

Earnings '28

x

28.69x

PE Ratio '28

=

AU$8.13b

Market Cap '28

AU$8.13b

Market Cap '28

/

231.20m

No. shares '28

=

AU$35.17

Share Price '28

AU$35.17 Share Price '28

Discounted to 2025 @ 6.90% p.a.

=

AU$28.79

Fair Value '25

AU$28.79 Fair Value '25

Converted to NZD @ 1.1329 AUD/NZD Exchange Rate

=

NZ$32.61

Fair Value '25